As of September 25, 2023, Axsome Therapeutics (NASDAQ: AXSM) has received evaluations from 8 analysts who have provided their 12-month price targets. These ratings have been collected over the past 3 months. The average price target for the company stands at $118.62, with a high estimate of $190.00 and a low estimate of $81.00.
Analyzing the ratings given by the analysts, 5 have expressed a bullish sentiment, indicating a positive outlook for Axsome Therapeutics. Additionally, 2 analysts have shown a somewhat bullish view, while 1 analyst remains indifferent. Interestingly, no analysts have expressed a somewhat bearish or bearish sentiment towards the company.
Comparing the current average price target to the previous average of $122.80, there has been a slight decrease of 3.4%. Despite this minor decrease, the consensus rating for Axsome Therapeutics stock remains as Moderate Buy. This rating is based on the 2 hold ratings, 7 buy ratings, and 1 sell rating provided by analysts.
Axsome Therapeutics, Inc.
Updated on: 05/12/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Strong Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
1:00 PM (UTC)
Date:05 December, 2023
|Analyst / firm||Rating|
AXSM Stock Performance: Slight Decrease in Value on September 25, 2023
On September 25, 2023, AXSM stock had a mixed performance, with a slight decrease in value. The stock opened at $72.61, lower than the previous day’s closing price of $73.42. Throughout the day, the stock’s price fluctuated within a range of $71.04 to $73.47. The trading volume for the day was 12,230 shares, which is significantly lower than the average volume of 846,922 shares over the past three months.
AXSM has a market capitalization of $3.5 billion. The company’s earnings growth last year was negative, with a decline of 32.79%. However, this year, AXSM has experienced positive earnings growth of 21.47%. Looking ahead, analysts predict a modest earnings growth of 1.40% over the next five years.
The price-to-sales ratio is 62.67, suggesting that investors are willing to pay a high premium for each unit of sales generated by the company. The price-to-book ratio is also high at 29.09, indicating that the stock is trading at a significant premium to its book value.
In comparison to other stocks in the health technology and biotechnology industry, AXSM’s performance on September 25, 2023, was relatively stable. Other companies in the sector, such as CRISPR Therapeutics, ImmunoGen Inc, Denali Therapeutics, and Blueprint Medicines, also experienced slight declines in their stock prices.
AXSM is expected to report its next earnings on November 9, 2023. Analysts forecast an earnings per share (EPS) of -$1.09 for this quarter. In the previous year, the company generated annual revenue of $50.0 million but incurred a net loss of -$187.1 million. The negative net profit margin of -373.99% indicates that the company’s expenses exceeded its revenue, resulting in significant losses.
Despite the negative financial figures, AXSM operates in the health technology sector, which is known for its potential growth and innovation. However, the lack of information about the company’s executives and its corporate headquarters in New York, New York, may raise some concerns for investors.
Overall, AXSM stock had a mixed performance on September 25, 2023, with a slight decrease in value. The company’s financial figures, such as its negative earnings growth last year and negative net profit margin, may raise some caution among investors. However, the positive earnings growth this year and the potential for growth in the health technology sector may still attract investors looking for long-term opportunities.
Promising Performances and Positive Indicators: Axsome Therapeutics Inc Stock Analysis and Forecast
On September 25, 2023, Axsome Therapeutics Inc (AXSM) stock showed promising performances based on the information provided by CNN Money. The 12 analysts offering 12-month price forecasts for AXSM had a median target of 107.26, with a high estimate of 180.00 and a low estimate of 84.00.
The consensus among 12 polled investment analysts is to buy stock in Axsome Therapeutics Inc. This rating has remained unchanged since August.
Axsome Therapeutics Inc reported a loss of -$1.09 earnings per share for the current quarter. However, the company’s sales reached $50.5 million. The reporting date for these financial results is set for November 9.
These positive indicators suggest that investors have confidence in Axsome Therapeutics Inc’s future prospects. The company’s strong sales performance also indicates a healthy market demand for its products.
Investors should conduct thorough research and consider their own risk tolerance before making any investment decisions.